Shenyi Yin

Abstract Decreased cross-presentation by antigen-presenting cells induces the scarcity of tumour-reactive T cells within the tumour bed, rendering in situ T cell rejuvenation through immunogenicity reprogramming highly desirable yet challenging1,2,3. Here we developed an intratumoural vaccination chimera (iVAC) to reprogram tumour cells into an antigen-presenting state (APC-like tumour cells) with restored anti-tumour immunity.

Study design and patients This is an observational trial. The aim of the study was to assess the feasibility and predictive value of a standardized PTC-based test to differentiate efficacy of the patients' clinical drug regimens. The study was conducted at Peking University Cancer Hospital and was approved by the local ethical review board. The study protocol was in accordance with the Declaration of Helsinki, Chinese law and Good Clinical Practice.

Little clusters with big promise Despite recent advances in medicine, identifying the optimal treatment regimen for each patient with cancer remains difficult and often imprecise. There are now multiple methods for analyzing a tumor’s drug sensitivity, including tumor organoids and patient-derived xenografts, but each has its own drawbacks such as a lack of tumor stroma or the time required to obtain results.